Sunitinib for the Treatment of Phaeochromocytomas and ParagangliomasSheng Zhang & Mingjuan Sun & Qin Wang & Hongxia Wang2025PDF
Baricitinib for Systemic Lupus Erythematosus: a Double-blind, Randomised, Placebo-controlled, Phase 3 Trial (SLE-BRAVE-I)Morand, Eric F & 26 more2023PDF
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trialBowman, Simon J & 30 more2022PDF
Etrolizumab as Induction and Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease (BERGAMOT): a Randomised, Placebo-controlled, Double-blind, Phase 3 TrialSandborn, William J & 30 more2023PDF
Everolimus Eluting Bioresorbable Vascular Scaffolds in Patients with Acute Coronary Syndromes: Two-year Results from the German-Austrian ABSORB RegistryMonique Tröbs, Stephan Achenbach & 9 more2021PDF
Sunitinib Impedes Brain Tumor Progression and Reduces Tumor-induced Neurodegeneration in the MicroenvironmentGökçe Hatipoglu, Stefan W. Hock & 7 more2015PDF
Design, Synthesis, and Biological Evaluation of SSE1806, a Microtubule Destabilizer That Overcomes Multidrug ResistanceFarhat Firdous, Sharon Riaz & 11 morePDF
Sunitinib for the Treatment of Phaeochromocytomas and Paragangliomas – Authors' ReplyEric Baudin & Julien Hadoux & Alfredo Berruti & Livia Lamartina & Matthieu Texier & Martin Fassnacht2025PDF
Incidence of Serotonin Syndrome in Patients Receiving Tedizolid and Concomitant Serotonergic AgentsYingsi Fang & Lloyd G. Clarke & Brandon J. Smith & Sunish Shah2024PDF
ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepimeMichael R. Jacobs, Ayman M. Abdelhamed, Caryn E. Good, Andrew R. Mack, Christopher R. Bethel, Steven Marshall, Andrea M. Hujer, Kristine M. Hujer, Robin Patel, David van Duin, Vance G. Fowler, Daniel D. Rhoads, David A. Six, Greg Moeck2024PDF